Manufacturing capacity for diagnostics increased at a rapid rate during the COVID-19
Once in-vitro diagnostics (IVDs) are quality assured and countries have policies in place to deploy diagnostic tools and technologies, products must be made available for purchase. Availability is critical for consumption and commercialization. For optimal diagnostic impact, products need to be in widespread use. Products thus need to be manufactured and produced in volumes based on global and national requirements.